Hydroxyurea Increases Plasma Concentrations of Microparticles and Reduces Coagulation Activation and Fibrinolysis in Patients with Sickle Cell Anemia
Authors:
- Denise Menezes BrunettaDBDenise Menezes Brunetta
- Gil Cunha De SantisGSGil Cunha De Santis
- Ana Cristina Silva-PintoASAna Cristina Silva-Pinto
- Luciana Correa Oliveira de OliveiraLOLuciana Correa Oliveira de Oliveira
- Dimas Tadeu CovasDCDimas Tadeu Covas
- 2 December 2014
- journal article
- clinical trial
- Published by S. Karger AG in Acta Haematologica
- Vol. 133 (3) , 287-294
Abstract
Microparticles (MPs) are present in healthy subjects and their concentration increases in patients at high risk of thrombosis. We evaluated 10 patients with sickle cell anemia (SCA) treated with hydroxyurea (HU) and 13 SCA patients without this treatment. MP concentrations were determined by flow cytometry. Coagulation was evaluated using the thrombin-antithrombin complex (TAT) and D-dimers. Total MP concentrations were increased in the HU-treated group (265 × 106/ml vs. 67.45 × 106/ml; p = 0.0026), as well as MPs derived from RBC (67.83 × 106/ml vs. 26.31 × 106/ml; p = 0.05), monocytes (51.31 × 106/ml vs. 9.03 × 106/ml; p = 0.0084), monocytes with tissue factor (TF) expression (2.27 × 106/ml vs. 0.27 × 106/ml; p = 0.0058), endothelium (49.42 × 106/ml vs. 7.23 × 106/ml; p = 0.007) and endothelium with TF (1.42 × 106/ml vs. 0.26 × 106/ml; p = 0.0043). Furthermore, the concentrations of TAT (7.56 vs. 10.98 µg/l; p = 0.014) and D-dimers (0.65 vs. 1.29 µg/ml; p = 0.007) were reduced with HU. The MP elevation may suggest a direct cytotoxic effect of HU. Another explanation is a cell surface increase secondary to a megaloblastic process, resulting in increased vesicle release. In our opinion, the known benefits of HU on SCA patients, along with the reduction in coagulation activation, surpass its potential detrimental effect on MPs. Future studies should elucidate the role of MPs and demonstrate their significance in different contexts. © 2014 S. Karger AG, BaselKeywords
This publication has 41 references indexed in Scilit:
- Fetal hemoglobin and hydroxycarbamide moduate both plasma concentration and cellular origin of circulating microparticles in sickle cell anemia childrenHaematologica, 2013
- Microparticle‐associated tissue factor activity, venous thromboembolism and mortality in pancreatic, gastric, colorectal and brain cancer patientsJournal of Thrombosis and Haemostasis, 2012
- Microparticles as a circulating source of procoagulant and fibrinolytic activities in the circulationThrombosis Research, 2012
- Biomarkers of Inflammation, Growth Factor, and Coagulation Activation in Patients With Sickle Cell DiseaseClinical and Applied Thrombosis/Hemostasis, 2011
- High levels of circulating leukocyte microparticles are associated with better outcome in acute respiratory distress syndromeCritical Care, 2011
- Sickle-cell diseaseThe Lancet, 2010
- Microparticles in Thrombosis and HemostasisSeminars in Thrombosis and Hemostasis, 2010
- Hydroxyurea Treatment of Myeloproliferative DisordersActa Medica Scandinavica, 2009
- Microvesicles in haemoglobinopathies offer insights into mechanisms of hypercoagulability, haemolysis and the effects of therapyBritish Journal of Haematology, 2008
- Redox-dependent impairment of vascular function in sickle cell diseaseFree Radical Biology and Medicine, 2007